NXL
NXL
NASDAQ · Health Care

Nexalin Technology Inc

$1.51
+0.02 (+1.34%)
Financial Highlights (FY 2026)
Revenue
21.1K
Net Income
-576,468
Gross Margin
79.7%
Profit Margin
-2,725.7%
Rev Growth
-38.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 79.7% 79.7% 58.5% 58.5%
Operating Margin -2,781.7% -2,503.5% 15.6% 16.3%
Profit Margin -2,725.7% -2,589.5% 10.4% 11.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 21.1K 34.6K 3.31M 3.62M
Gross Profit 16.8K 27.6K 1.94M 2.12M
Operating Income -588,209 -866,145 514.6K 589.5K
Net Income -576,468 -848,856 342.9K 405.7K
Gross Margin 79.7% 79.7% 58.5% 58.5%
Operating Margin -2,781.7% -2,503.5% 15.6% 16.3%
Profit Margin -2,725.7% -2,589.5% 10.4% 11.2%
Rev Growth -38.9% -38.9% +22.5% +6.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 3.24M 3.21M
Total Equity — — 3.39M 3.33M
D/E Ratio — — 0.95 0.96
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -588,305 -914,413 846.1K 883.2K
Free Cash Flow — — 192.0K 243.4K